About this Course
This course is a recorded (home study version) of the 2024 CE Finale Encore Webinars.
Learning Objectives
Upon completion of this application based CE Activity, a pharmacist will be able to:
| 1. Identify clinical characteristics of the behavioral symptoms of dementia (BSD) including agitation, psychosis, and sleep disturbances |
| 2. Discuss medications currently used in the management of BSD along with emerging pharmacologic therapy options |
| 3. Determine the most appropriate pharmacologic treatment option for a patient with behavioral symptoms of dementia based on patient-specific factors |
Release and Expiration Dates
Released: December 13, 2024
Expires: December 13, 2027
Course Fee
$17 Pharmacist
ACPE UAN
0009-0000-24-048-H01-P
Session Code
24RW48-YXF98
Accreditation Hours
1.0 hours of CE
Additional Information
How to Complete Evaluation: When you are ready to submit quiz answers, go to the BLUE take test/evaluation button. Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!
Accreditation Statement
| The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |  |
Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-24-048-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.
Grant Funding
There is no grant funding for this activity.
Faculty
Kristin Waters, PharmD, BCPS, BCPP
Assistant Clinical Professor
UConn School of Pharmacy
Storrs, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
- Dr. Waters is on the Johnson and Johnson speakers' bureau, but the information discussed here has no overlap. All financial relationships with ineligible companies have been mitigated.
Disclaimer
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Content
Handouts
Post Test
Behavioral Symptoms of Dementia Assessment Questions
- Which of the following is a symptom of agitation in dementia?
- Hallucinations
- Restless leg syndrome
- Throwing objects
- A 64-year-old patient has a PMH of AD, hypertension, urinary incontinence, and insomnia. Recently, they have been increasingly agitated throughout both the day and night. Symptoms primarily include pacing and verbally repeating the same phrases many times. Non-pharmacologic intervention is mildly effective, but the patient’s caregiver is requesting pharmacologic intervention as well.
Current medications:
Amlodipine 10 mg po daily
Oxybutynin 10 mg po daily
Diphenhydramine 25 mg po nightly prn insomnia
Cetirizine 10 mg po daily
Melatonin 6 mg po nightly Which of the following is the best first step in managing the patient’s agitation?
- Discontinue melatonin
- Reduce anticholinergic load
- Reduce dose of amlodipine
3. The patient and caregiver agree to discontinuation of the cetirizine and diphenhydramine. They feel strongly that the oxybutynin improves their quality of life by allowing them to not become incontinent of urine overnight. Unfortunately, several weeks later the agitation symptoms persist. Which of the following is the best recommendations at this time?
a. Initiate citalopram
b. Initiate haloperidol
c. Initiate risperidone
- A 71-year-old patient with vascular dementia recently started insisting that unknown people were living in his attic. He says he can hear the intruders talking during the night but they hide whenever someone goes up to check. The patient is extremely distressed about this and is trying to obtain a firearm to protect his family from these intruders.
Which of the following pharmacologic recommendations may be appropriate?
- Brexpiprazole
- Trazodone
- Haloperidol
- The patient’s symptoms improve significantly after starting brexpiprazole. However, he is still very restless at night and wakes up frequently. He reports being “exhausted” each day. Which of the following would be the best pharmacologic option?
- Melatonin
- Eszopiclone
- Suvorexant
6. Which medication approved for Parkinson’s disease psychosis has demonstrated the ability to prolong time to relapse of psychosis in Alzheimer’s disease?
a. Brexpiprazole
b. Pimavanserin
c. Dexmedetomidine
7. Which of the following behavioral symptoms of dementia is the most common?
a. Apathy
b. Psychosis
c. Anxiety
VIDEO